ArticleNeuroradiology2018
Metabolic topography of autoimmune non-paraneoplastic encephalitis.
Article in Neuroradiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- [18F]FDG brain PET and clinical symptoms in different autoantibodies of autoimmune encephalitis: a systematic review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Pooled it
- BrainEuropean journal of nuclear medicine and molecular imaging · 2021Pooled it
- Article
- Comparison ofEuropean journal of nuclear medicine and molecular imaging · 2025Article
- Clinical Features of Glutamic Acid Decarboxylase-65 Neurological Autoimmunity: A Case Series From China.CNS neuroscience & therapeutics · 2025Article
- Towards an optimal diagnostic and prognostic model based on semi-quantitative assessment ofFrontiers in immunology · 2025Article
- Enhancing the clinical diagnosis of the acute and subacute phases of autoimmune encephalitis and predicting the risk factors: the potential advantages of 18F-FDG PET/CT.BMC medical imaging · 2023Article
- Typical metabolic pattern ofBMC neuroscience · 2023Article
- Hypometabolism of the left middle/medial frontal lobe on FDG-PET in anti-NMDA receptor encephalitis: Comparison with MRI and EEG findings.CNS neuroscience & therapeutics · 2023Article
- Spatial and Ecological Factors Modulate the Incidence of Anti-NMDAR Encephalitis-A Systematic Review.Biomedicines · 2023Review
- Brain Metabolic Alterations in Seropositive Autoimmune Encephalitis: AnBiomedicines · 2023Article
- Cortical metabolic characteristics of anti-leucine-rich glioma-inactivated 1 antibody encephalitis based onFrontiers in neurology · 2023Article
- Usefulness of brain FDG PET/CT imaging in pediatric patients with suspected autoimmune encephalitis from a prospective study.European journal of nuclear medicine and molecular imaging · 2022Observational
- Cortical and Subcortical Dysmetabolism Are Dynamic Markers of Clinical Disability and Course in Anti-LGI1 Encephalitis.Neurology(R) neuroimmunology & neuroinflammation · 2022Article
- Decrease in the cortex/striatum metabolic ratio on [European journal of nuclear medicine and molecular imaging · 2022Article
- The Detection of Invisible Abnormal Metabolism in the FDG-PET Images of Patients With Anti-LGI1 Encephalitis by Machine Learning.Frontiers in neurology · 2022Article
- Recognition of seizure semiology and semiquantitative FDG-PET analysis of anti-LGI1 encephalitis.CNS neuroscience & therapeutics · 2021Article
- [Neurology · 2021Article
- Autoimmune limbic encephalitis related to SARS-CoV-2 infection: Case-report and review of the literature.Brain, behavior, & immunity - health · 2021Article
- Subcortical Hypermetabolism Associated With Cortical Hypometabolism Is a Common Metabolic Pattern in Patients With Anti-Leucine-Rich Glioma-Inactivated 1 Antibody Encephalitis.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeF-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) is emerging to be a useful tool in supporting the diagnosis of AIE. In this study, we describe the metabolic patterns on F-18 FDG PET imaging in AIE.
methodsTwenty-four antibody-positive patients (anti-NMDA-15, anti-VGKC/LGI1-6, and anti-GAD-3), 14 females and 10 males, with an age range of 2-83 years were included in this study. Each PET study was evaluated visually for the presence of hypometabolism or hypermetabolism and semiquantitatively using Cortex ID (GE) and Scenium (Siemens) by measuring regional Z-scores. These patterns were correlated with corresponding antibody positivity once available.
resultsVisually, a pattern of hypometabolism, hypermetabolism, or both in various spatial distributions was appreciated in all 24 patients. On quantitative analysis using scenium parietal and occipital lobes showed significant hypometabolism with median Z-score of -3.8 (R) and -3.7 (L) and -2.2 (R) and -2.5 (L) respectively. Two-thirds (16/24) showed significant hypermetabolism involving the basal ganglia with median Z-score of 2.4 (R) and 3.0 (L). Similarly on Cortex ID, the median Z-score for hypometabolism in parietal and occipital lobes was -2.2 (R) and -2.4 (L) and -2.6 (R) and -2.4 (L) respectively, while subcortical regions were not evaluated. MRI showed signal alterations in only 11 of these patients.
conclusionThere is heterogeneity in metabolic topography of AIE which is characterized by hypometabolism most commonly involving the parietal and occipital cortices and hypermetabolism most commonly involving the basal ganglia. Scenium analysis using regional Z-scores can complement visual evaluation for demonstration of these metabolic patterns on FDG PET.
Indexed as
Identifiers
29255919What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.